Skip to content
The science of gene therapies is progressing at a remarkable pace, but if these medicines are going to reach patients, trends in investment and […]
CEOs say market must keep up with the science of gene therapies Read More »
As the 13th Ministerial Conference of the World Trade Organization (WTO) kicks off (Feb. 26-29), the expansion of the COVID-19 IP waiver remains a
Why the WTO should focus on addressing trade-related aspects of pandemic preparedness Read More »
On February 21, the Biotechnology Innovation Organization’s (BIO) soon-to-be President & CEO, John F. Crowley, joined an event about biomarkers and rare disease regulatory
How biomarkers can support regulatory rare disease pathways Read More »
The Covid-19 pandemic undoubtedly reshaped the landscape of healthcare and vaccine development in ways we have yet to imagine. As we navigate through another
The future of pandemic defense leverages science and tech Read More »
As scientists and leading biotech companies are scrambling to achieve life-changing breakthroughs and treatments, sickle cell disease (SCD) is on the cusp of a
Sickle cell disease marks a few milestones, but more needs to be done Read More »
Bio.News recently caught up with Dr. Debbie Yaver, Chief Scientific Officer (CSO) of Nature’s Fynd. Nature’s Fynd is a Chicago, Illinois-based food tech company
Dr. Debbie Yaver: inaugural BIO Rosalind Franklin Award winner Read More »
Before heading home for President’s Day recess, Members of Congress made progress on a few priorities for the biotech industry. Of note, the House
House introduces bill to reauthorize PPRV Read More »
Clinical trial diversity used to be seen “as kind of a ‘nice to have,’” said Gary A. Puckrein, Ph.D., President and CEO of the
Black History Month reminds us of the dire need for clinical trial diversity Read More »
AstraZeneca recently announced that it is investing $300 million in a Rockville, MD facility “to launch its life-saving cell therapy platforms in the US
AstraZeneca announces new $300 million Maryland facility Read More »
GSK believes that “innovation starts when we stop to listen.” In 2023, GSK took a moment to engage with a variety of people across
GSK survey shows optimism for the future of biotech innovation Read More »
